Please assess the completion status of the following clinical trial:

Trial Title: PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 and ≤ 75 years old with de novo diagnosis of AML or high-risk myelodysplastic syndrom for whom intensive induction chemotherapy is anticipated within 10 days after admission~* Patients willing to donate stool samples and to follow protocol recommendations~* Signature of informed and written consent~Exclusion Criteria:~* Acute promyelocytic leukemia (AML-M3)~* Known allergy or intolerance to trehalose or maltodextrin~* Pregnancy: positive urinary or blood test in female of childbearing potential~* Severe disease with a life expectancy \< 3 months~* Other ongoing interventional protocol that might interfere with the study~* Non eligibility for collection of autologous stools upon admission:~  * Patients refusing to consent~ * Antibiotherapy at the time of study inclusion ≥ 4 days~ * Concomitant or previous diagnosis of a significant inflammatory bowel disease (UC, CD) or other progressive digestive disease requesting treatment or further medical exploration~ * Presence of severe colitis of any etiology at the time of admission or severe digestive disorders (acute or chronic diarrhea) within 3 months preceding inclusion~ * Patient getting a recent colonoscopy (within 3 months preceding inclusion)~* Detection of MDRB, pathogenic bacteria, parasites, norovirus and/or rotavirus during screening of autologous stool collected at baseline~* Non eligibility for inoculum transplantation: persistent mucositis, colitis, or haemorrhoids, presence of blood in more than 50% of patient's faeces the week preceding the transplantation~* Non feasibility of inoculum procedure: patient refusal; technical or biological mismatch of the inoculum~* Absence of effective contraceptive method for female of childbearing potential~* Lactation~* Inability to give an informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Autologous Fecal Microbiota Transplantation (Type: EXPERIMENTAL): Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).